Anocca Appoints Martin Welschof to Board of Directors

Read full release

SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata

Read full release

MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

Read full release

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023

Read full release

BC Platforms Acquires Medexprim, Paving the Way for Global Leadership in Real-World Data and Real-World Evidence Analytics

Read full release

TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023

Read full release

GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100

Read full release

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

Read full release

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Read full release

AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia

Read full release

ExeVir Bio Appoints a Chief Scientific Officer

Read full release

GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development

Read full release

LEX Diagnostics Appoints Chief Technology Officer

Read full release

EnteroBiotix appoints Elmar Schnee as Executive Chairman

Read full release

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Read full release

ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

Read full release

Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Read full release

TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor

Read full release

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

Read full release

Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders

Read full release

SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

Read full release

aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress

Read full release

Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

Read full release

Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant

Read full release

LEX Diagnostics Appoints Scott O’Brien as LEX Board Member

Read full release

Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology

Read full release

TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials

Read full release

LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer

Read full release

Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer

Read full release

Etcembly Announces Breakthrough in Optimising TCR Assets

Read full release

Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint

Read full release

Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Read full release

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

Read full release

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

Read full release

TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

Read full release

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Read full release

Valo Therapeutics Announces Scientific Advisory Board

Read full release

Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies

Read full release

Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.

Read full release

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Read full release

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Read full release

GPCR Therapeutics Expands Scientific Advisory Board

Read full release

MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

Read full release

Etcembly Appoints Scott Cuthill as Chief Business Officer

Read full release

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

Read full release

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Read full release

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Read full release

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Read full release

Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO

Read full release

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Read full release

Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development

Read full release

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies

Read full release

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Read full release

Amphista Therapeutics Appoints CBO, Beverley Carr

Read full release

BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia

Read full release

Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy

Read full release

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Read full release

Anocca appoints Jacob Michlewicz as CFO

Read full release

Vaccitech to join Brookfield’s Harwell Campus

Read full release

Vaccitech Oncology Limited’s ChAdOx1/MVA prime-boost immunotherapeutic shows preclinical potential as a novel cancer treatment

Read full release

BC Platforms Launches packaged end-to-end solution for NGS laboratories with Sentieon to accelerate adoption of NGS testing

Read full release

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

Read full release

Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab

Read full release

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia

Read full release

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

Read full release

Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Read full release

Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug

Read full release

Vaccitech Announces Pricing of Initial Public Offering

Read full release

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Read full release

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Read full release

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

Read full release

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Read full release

BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19

Read full release

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

Read full release

InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19

Read full release

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Read full release

BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform

Read full release

Oxford University breakthrough on global COVID-19 vaccine

Read full release

BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research

Read full release

First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients

Read full release

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

Read full release

Amphista Therapeutics appoints Ian Churcher as CSO

Read full release

Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate

Read full release

Oxford COVID-19 vaccine begins human trial stage

Read full release

Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology

Read full release

Amphista Therapeutics raises $7.5m Series A round

Read full release

World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research

Read full release

BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers

Read full release

BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics

Read full release

Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019

Read full release

AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia

Read full release

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Read full release

Amphista Therapeutics Appoints CBO, Beverley Carr

Read full release

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Read full release

Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Read full release

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Read full release

Amphista Therapeutics appoints Ian Churcher as CSO

Read full release

Amphista Therapeutics raises $7.5m Series A round

Read full release

Anocca Appoints Martin Welschof to Board of Directors

Read full release

Anocca secures EUR25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer

Read full release

Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development

Read full release

Anocca appoints Jacob Michlewicz as CFO

Read full release

BC Platforms Acquires Medexprim, Paving the Way for Global Leadership in Real-World Data and Real-World Evidence Analytics

Read full release

Partnership of BC Platforms, Euformatics and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Read full release

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Read full release

BC Platforms Expands Partnership with Thailand’s Bumrungrad International Hospital to Accelerate Adoption of Precision Medicine in Southeast Asia

Read full release

BC Platforms Launches packaged end-to-end solution for NGS laboratories with Sentieon to accelerate adoption of NGS testing

Read full release

BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19

Read full release

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Read full release

BC Platforms Rings in an Award-Winning Year with record growth in its BCRQUEST.com global data partner network and BC|INSIGHT Discovery and Research platform

Read full release

BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network BCRQUEST.com to advance Personalized Healthcare Research

Read full release

World’s leading biobanks join BC Platforms’ Global Data Partner Network to advance personalized healthcare research

Read full release

BC Platforms partners with Dante Labs to build Europe’s largest Next Generation Sequencing laboratory for private and public customers

Read full release

BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA to Extend Data Analytics in Genomics

Read full release

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Read full release

Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.

Read full release

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Read full release

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

Read full release

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

Read full release

Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019

Read full release

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Read full release

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Read full release

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Read full release

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Read full release

Vaccitech to join Brookfield’s Harwell Campus

Read full release

Vaccitech Oncology Limited’s ChAdOx1/MVA prime-boost immunotherapeutic shows preclinical potential as a novel cancer treatment

Read full release

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

Read full release

Vaccitech Announces Pricing of Initial Public Offering

Read full release

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Read full release

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Read full release

Oxford University breakthrough on global COVID-19 vaccine

Read full release

First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients

Read full release

Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate

Read full release

Oxford COVID-19 vaccine begins human trial stage

Read full release

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

Read full release

Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Read full release

Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology

Read full release

Valo Therapeutics Announces Scientific Advisory Board

Read full release

Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies

Read full release

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

Read full release

Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO

Read full release

Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab

Read full release

Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology

Read full release

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023

Read full release

TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023

Read full release

TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor

Read full release

TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials

Read full release

TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

Read full release

Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy

Read full release

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

Read full release

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

Read full release

Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant

Read full release

Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint

Read full release

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia

Read full release

Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug

Read full release

InVixa announces licensing deal with University of California, Davis for the commercialization of novel inhaled statins for the treatment of COVID-19

Read full release

ExeVir Bio Appoints a Chief Scientific Officer

Read full release

ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

Read full release

LEX Diagnostics Appoints Chief Technology Officer

Read full release

LEX Diagnostics Appoints Scott O’Brien as LEX Board Member

Read full release

LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer

Read full release

MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

Read full release

MitoRx Therapeutics Announces Seed Financing to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases

Read full release

SiSaf Announces Completion of Patient Enrolment in Phase II Trial of Bio-Courier® Drug Formulation for the Treatment of Mild/Moderate Alopecia Areata

Read full release

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Read full release

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

Read full release

SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

Read full release

SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation

Read full release

SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Read full release

SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies

Read full release

EnteroBiotix appoints Elmar Schnee as Executive Chairman

Read full release

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

Read full release

GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100

Read full release

GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development

Read full release

GPCR Therapeutics Expands Scientific Advisory Board

Read full release